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BACKGROUND AND PURPOSE
The importance of tyrosine kinases in airway smooth muscle (ASM) contraction is not fully understood. The aim of this study
was to investigate the role of Src-family kinases (SrcFK) and focal adhesion kinase (FAK) in GPCR-mediated ASM contraction
and associated signalling events.
EXPERIMENTAL APPROACH
Contraction was recorded in intact or α-toxin permeabilized rat bronchioles. Phosphorylation of SrcFK, FAK, myosin light-chain-
20 (MLC20) and myosin phosphatase targeting subunit-1 (MYPT-1) was evaluated in cultured human ASM cells (hASMC). [Ca
2+]i
was evaluated in Fura-2 loaded hASMC. Responses to carbachol (CCh) and bradykinin (BK) and the contribution of SrcFK and FAK
to these responses were determined.
KEY RESULTS
Contractile responses in intact bronchioles were inhibited by antagonists of SrcFK, FAK and Rho-kinase, while after α-toxin
permeabilization, they were sensitive to inhibition of SrcFK and Rho-kinase, but not FAK. CCh and BK increased phosphorylation
of MYPT-1 and MLC20 and auto-phosphorylation of SrcFK and FAK. MYPT-1 phosphorylation was sensitive to inhibition of
Rho-kinase and SrcFK, but not FAK. Contraction induced by SR Ca2+ depletion and equivalent [Ca2+]i responses in hASMC were
sensitive to inhibition of both SrcFK and FAK, while depolarization-induced contraction was sensitive to FAK inhibition only. SrcFK
auto-phosphorylation was partially FAK-dependent, while FAK auto-phosphorylation was SrcFK-independent.
CONCLUSIONS AND IMPLICATIONS
SrcFK mediates Ca2+-sensitization in ASM, while SrcFK and FAK together and individually inﬂuence multiple Ca2+ inﬂux pathways.
Tyrosine phosphorylation is therefore a key upstream signalling event in ASM contraction and may be a viable target for
modulating ASM tone in respiratory disease.
Abbreviations
ASM, airway smooth muscle; hASMC, cultured human airway smooth muscle cells; KPSS, PSS with 80mM equimolar
substitution of Na+ for K+; MLC20, myosin light-chain 20 KDa subunit; MLCP, myosin light-chain phosphatase; MYPT-1,
myosin phosphatase targeting subunit-1; ROCE, receptor-operated Ca2+ entry; SOCE, store-operated Ca2+ entry; VOCE,
voltage-operated Ca2+ entry
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Introduction
Airway smooth muscle (ASM) tone is subject to regulation by
cholinergic, catecholamine and NANC neurotransmitters as
well as local inﬂammatory mediators. In healthy airways,
muscle tone is normally low, providing a low resistance path
for airﬂow. However, contraction may be enhanced in re-
sponse to chemical irritants or allergens, particularly in lower
respiratory tract bronchioles (Gilbert and Auchincloss, 1989;
Pinelli et al., 2009). In asthma, airway resistance is increased,
partly due to increased basal tone and hypersensitivity to
constrictor stimuli in these bronchioles (Doeing and Solway,
2013; Meurs et al., 2008).
Smoothmuscle contractile force depends on the degree of
myosin light-chain-20 (MLC20) phosphorylation, which is in
turn determined by the balance between Ca2+-dependent ac-
tivation of myosin light-chain kinase (MLCK) and Ca2+-inde-
pendent inhibition of myosin light-chain phosphatase
(MLCP), as well as the formation and recruitment of myoﬁla-
ments (Gunst et al., 2003; Somlyo and Somlyo, 2003).
Increases in [Ca2+]i result from Ca
2+ release from the sarco-
endoplasmic reticulum (SR) and a combination of Ca2+ entry
through receptor-operated, store-operated and voltage-
operated Ca2+ channels (ROCE, SOCE and VOCE, respec-
tively). Inhibition of MLCP occurs via phosphorylation of
myosin phosphatase targeting subunit-1 (MYPT-1), primarily
by Rho-kinase (Feng et al., 1999), resulting in a further
increase in MLC20 phosphorylation and contraction without
the need for a further increase in [Ca2+]i (Somlyo and Somlyo,
2003). Although it is likely that bronchoconstrictors act via a
combination of the above pathways, the precise mechanisms
through which Ca2+ inﬂux and Rho-kinase activity are medi-
ated by GPCRs are not fully understood.
Src family kinases (SrcFK) and focal adhesion kinase (FAK)
are widely expressed non-receptor tyrosine kinases (TKs) im-
portant in many aspects of cellular function, being activated
in response to various stimuli including growth factors,
GPCRs, reactive oxygen species and adhesion. SrcFK and
FAK are often described as beingmutually dependent or recip-
rocally activated, especially when associated with integrin
engagement and/or growth factor receptor activation (Owen
et al., 1999; Ishigaki et al., 2011). An effect of TKs on ASM tone
was ﬁrst suggested by the relaxant effect of non-selective tyro-
sine kinase inhibitors on rat isolated bronchioles (Chopra
et al., 1997). Subsequently, selective inhibition of SrcFK and
FAK was shown to depress GPCR-induced contraction in
human, rodent or canine upper airways (Tang and Gunst,
2001; Katsumoto et al., 2013). FAK was linked to elevated
[Ca2+]i in response to various stimuli in trachea, but the
relative inﬂuence of the kinase on VOCE, ROCE or SOCE or
on Rho-kinase was not determined (Tang et al., 1999; Tang
and Gunst, 2001). SrcFKs have been identiﬁed as upstream
mediators of Rho-kinase in vascular smooth muscle (Nakao
et al., 2002; Knock et al., 2008), but neither this relationship
nor the inﬂuence of SrcFK on GPCR [Ca2+]i responses has
yet been examined in ASM. To our knowledge, only one
previous study has examined the involvement of SrcFK or
FAK speciﬁcally in the contraction of intralobar bronchioles,
and this was limited to the role of SrcFK in mediating
sensitization of rat bronchioles to muscarinic agonists (Sakai
et al., 2010).
In this study, we hypothesized that SrcFK and FAK mediate
GPCR-induced ASM contraction via multiple signalling path-
ways and examined their inﬂuence on Rho-kinase-dependent
MLCP inhibition/Ca2+-sensitization and on SOCE/ROCE and
VOCE Ca2+ entry pathways, in intra-lobar bronchioles of rat
and cultured human ASM cells (hASMC). We found that
SrcFK, most likely c-Src itself, modulate Rho-kinase dependent
Ca2+-sensitization, but FAK does not, and that the two tyrosine
kinases differentially regulate SOCE/ROCE and VOCE. We
also suggest the existence of two subpopulations of GPCR-
activated SrcFK, one being FAK-dependent and the other
FAK-independent.
Methods
Rats and tension measurement by wire
myography
All animal care and experimental procedures complied with
UK legislation under the Animals (Scientiﬁc Procedures) Act
1986 Amendment Regulations (SI 2012/3039) and were
Tables of Links
TARGETS
Ion channelsa Enzymesb
Store-operated Ca2+ channels FAK
Voltage-gated Ca2+ channels MLCK
PYK2
Src family kinases
Rho-kinase (ROCK)
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are permanently archived in the Concise Guide
to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
LIGANDS
Bradykinin (BK) GTP
Carbachol (CCh) Nifedipine
Cyclopiazonic acid (CPA) Y27632
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deemed to be as humane as possible. All results involving an-
imals are reported in accordance with the ARRIVE guidelines
for reporting experiments involving animals (McGrath et al.,
2010). A total of 98 rats were used. Male Wistar rats (~250 g)
had free access to food and water and were maintained on a
12:12 h light/dark schedule. The rats were killed by an i.p.
injection of sodium pentobarbital and the lungs and trachea
were immediately removed. First or second-order intralobar
bronchioles (~2mm length) were dissected free of surround-
ing parenchyma and mounted on a wire myograph (DMT.
dk), bathed in PSS (in mM: 118 NaCl; 24 NaHCO3; 1 MgSO4;
4 KCl; 5.56 glucose; 0.435 NaH2PO4; 1.8 CaCl2, pH 7.4),
gassed with 95% air, 5% CO2 at 37°C. Bronchioles were
incrementally stretched and alternately exposed to PSS con-
taining 80mM [K+] (equimolar substitution for Na+, KPSS)
until the point on the length tension curve at which muscle
length was optimum for active tension development was
achieved, as described previously (Moir et al., 2003). Viability
for contraction experiments was conﬁrmed by a response of
at least 3mN to the last challenge with KPSS. Bronchiole
internal diameter after stretch was typically in the range
300–800 μm.
Speciﬁc examination of the Rho-kinase dependent Ca2+-
sensitization component of contraction was achieved by
permeabilizing myograph-mounted bronchioles with
α-haemolysin (α-toxin). PSS was ﬁrst exchanged for relaxing
solution (pCa = 10, in mM: 200 PIPES; 100Mg(Ms)2; 1000
KMS; 100 K2EGTA; 5 Na2ATP; 10 Na2creatine phosphate,
pH 7.1), gassed with air at 26°C. α-toxin (60 μgml-1) was then
applied in relaxing solution with pCa raised to 6.7 for 30min,
permeabilization being conﬁrmed by the development of
active tension. pCa was adjusted via proportionate substitu-
tion of K2EGTA for CaEGTA, with 100 CaEGTA, 0 K2EGTA
being equivalent to pCa4.5. Contractile responses to
bronchoconstrictors were conducted at pCa 6.5 (~300 nM
[Ca2+]), which induced a contraction equivalent to 10-20%
of that achieved by pCa 4.5. GTP 1 μM and 10 μM
cyclopiazonic acid (CPA) were included to support G-protein
signalling and to prevent the inﬂuence of SR Ca2+ release on
contraction respectively.
Human tissue and cell culture
Donations of human tissue were obtained following written
informed consent and with the approval of the South East
London Research Ethics Committee, REC reference number
10/H0804/66. All clinical procedures conformed to the
standards set by the latest Declaration of Helsinki. hASMC
were obtained from healthy volunteers (n = 11; 7 women, 4
males; age range 22–53 years; life-long absence of respiratory
symptoms; lung functions within normal limits) by deep
endobronchial biopsy. ASM bundles were bathed in DMEM
containing 10% FBS, L-glutamine (2mM), sodium pyruvate
(1mM), non-essential amino acids and amphotericin B
(2 μgml-1), and subjected to enzymatic digestion in nomi-
nally Ca2+-free HEPES buffer containing: 5.56mM glucose,
2mg ml-1 collagenase Type XI, 1mgml-1 papaine, 1mgml-1
trypsin inhibitor and 1mM DTT, for 30min at 37°C. Cells
were then dispersed into culture ﬂasks containing DMEM
(plus supplements) and incubated at 37°C, pH 7.4. Smooth
muscle phenotype was conﬁrmed by positive staining with
anti-smooth muscle α-actin, anti-desmin and anti-calponin,
with Alexa Fluor®488 labelled secondary antibody
(Lifetechnologies) and with TRITC-labelled phalloidin to
conﬁrm the presence of stress ﬁbres in resting cells
(Supporting Information Fig. S1). Cells were used for experi-
ments at passages 4–9, grown to conﬂuence and serum
starved for 7 days in DMEM plus supplements, and the
addition of 1% BSA, 5 μgml-1 transferrin, 1 μM insulin and
100 μM ascorbate.
siRNA design and transfection
Two siRNAs against human SRC (GenBank accession no.
NM_005417) were designed as described previously (Reynolds
et al., 2004; Ui-Tei et al., 2004). The 19 nucleotide target
sequences (SRC-siRNA1: position 1489–1507 and SRC-siRNA2:
position 1684–1702) were synthesized into 64–65 mer oligonu-
cleotides with BamHI/HindIII overhangs (Sigma Aldrich) and
cloned into the expression vector pSilencer 3.0-H1, containing
pmaxGFP (Ambion Inc.). All clones were puriﬁed using an
EndoFree Plasmid Maxi Kit (Qiagen Ltd) and sequenced
(Geneservice Ltd). hASMC were transfected using the Basic
Nucleofector® Kit and nucleofector device (Amaxa Biosystems).
After 72h, the transfection efﬁciency was >90%, conﬁrmed by
ﬂuorescence microscopy.
Protein lysate preparation and western blot
Cultured hASMCs were treated in serum-free DMEM at 37°C.
Preliminary studies showed that phosphorylation responses,
although sustained for at least 5min, peaked at ~30 s, so all
subsequent acute treatments were for 30 s. Cells were imme-
diately washed twice with ice-cold PBS, followed immediately
by application of cell lysis buffer (NEB) containing 1% phos-
phatase inhibitor cocktails 2 and 3 and 1% protease inhibitor
cocktail (all Sigma). Cells were scraped into a tube and
agitated before being placed on ice. Rat trachealis muscle
was dissected free of adjoining cartilage, and epithelium was
removed by scraping. Acute treatments were conducted in
PSS/5% CO2, at 37°C, before the tissue was snap frozen in
liquid nitrogen, pulverized and lysed in cell lysis buffer. All
lysates were centrifuged at 9.2x g, and the supernatants were
stored at 80°C.
Samples were boiled in NuPAGE LDS Sample Buffer
(Invitrogen) at 95°C for 5min before being loaded onto
4–12% NuPAGE Bis-Tris gels (Invitrogen) for SDS-PAGE. Sam-
ple protein content was determined using the bicinchoninic
acid assay, calibrated against BSA protein standards, to enable
loading of ~20 μg of protein per lane. Gels were run at 180V
for 1 h using an Xcell SureLock Mini-Cell (Invitrogen) and
MOPS running buffer (Invitrogen). Protein was transferred
to a nitrocellulose membrane (Amersham) in 25mM Tris,
192mM glycine and 20% methanol, at 35 V for 1 h.
Membranes were blocked with 5% skimmed milk in Tris
buffered saline (TBS) for 1 h at room temperature, followed
by incubation with speciﬁc anti-phospho-protein primary
antibody (typically 1:1000 dilution) in TBS with 1%
skimmed milk and 0.1% Tween-20 (TBS-T), overnight at
4°C. Following washes in TBS-T, HRP-conjugated secondary
antibody (typically 1:5000 dilution) was applied for 1 h at
room temperature, followed by a ﬁnal wash in TBS-T.
‘Phospho’ proteins were visualized with Super-Signal West
Tyrosine kinases in airway smooth muscle BJP
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Femto chemi-luminescent Substrate (Thermo scientiﬁc).
Membranes were then stripped in Restore western blot strip-
ping buffer (Thermo Scientiﬁc), re-blocked and re-incubated
with corresponding ‘total’ antibody and appropriate secondary
antibodies, as above. ‘Total’ proteins were visualized with
either ECL plus or ECL prime (Amersham, GE healthcare).
Images were captured and quantiﬁed using the ChemiDoc
XRS+ gel-imaging system (Biorad). An estimate of the propor-
tion of target protein that was phosphorylated was calculated
as a ratio of ‘phospho’ over ‘total’ signal for each protein band
from each gel, and the effects of acute treatments on these
ratios was expressed as a percentage of control (untreated
samples run on the same gel).
[Ca2+]i measurement
Cultured hASMCs were grown on glass cover-slips until 70%
conﬂuent, followed by 7 days of serum starvation. Cells were
loaded with 1 μM Fura PE-3/AM in HBSS (containing in mM:
0.49 MgCl, 0.41 MgSO4, 4 KCl, 0.44 KH2PO4, 4.2 NaHCO3,
120 NaCl, 0.34 Na2HPO4, 20 HEPES and 2 CaCl) at room
temperature for 40min. Coverslips were mounted on an up-
right microscope and cells perfused with HBSS, containing
test reagents as required. Changes in [Ca2+]i were measured
as a ratio of 340 nm over 380 nm emission intensities with
a ×20 oil immersion UV objective and a microspectro-
ﬂuorimeter (CairnResearch Ltd., U.K.). For each coverslip,
ratios obtained in zero [Ca2+]o and the absence of drug
were taken as background ﬂuorescence (auto-ﬂuorescence +
residual basal [Ca2+]i) and subtracted from all subsequent
measurements.
Materials and reagents
Antibodies were obtained from cell signalling (anti-phospho-
Src (tyr416); anti-Src; anti-phospho-FAK (Y397); anti-phospho-
FAK (Y576/577); anti-FAK; anti-phospho-MLC (S19); anti-MYPT1;
anti-MLC), Millipore (anti-phospho-MYPT1 (T696)), Sigma
(anti-rabbit IgG; anti-mouse IgG). Kinase inhibitors were obtai-
ned from Sigma ((1R, 4r)-4((R)-1-aminoethyl)-N-(pyridine-4-yl)
cyclohexane carboxamide (Y27632); 6-[4-(3-methanesulfonyl-
benzylamino)-5-triﬂuoromethyl-pyrimidin-2-ylamino]-3,4-dihy-
dro-1H-quinolin-2-one (PF-573228); N-[2-[[[2-[(2,3-dihydro-2-
oxo-1H-indol-5-yl)amino]-5-(triﬂuoromethyl)-4-pyrimidinyl]
amino]methyl]phenyl]-N-methyl-methanesulfonamidehydrate
(PF-431396) or Calbiochem: (4-amino-5-(4-chlorophenyl)-7-
(dimethylethyl) pyrazolo[3,4-d]pyrimidine (PP2); 4-amino-
7-phenylpyrazol[3,4-d]pyrimidine (PP3). Cell culture and
western blot materials were obtained from Cell Signalling,
Invitrogen, GE Healthcare or Thermo Scientiﬁc. Nifedipine,
YM58483, and cyclopiazonic acid and α-haemolysin were
from Sigma.
Data analysis and statistics
All values are expressed as mean ± SEM. Non-linear regres-
sion curve ﬁtting was performed with SigmaPlot 10. Carba-
chol (CCh) concentration-response curves were ﬁtted using
the Hill equation for the calculation of PD2 (-LogM EC50)
and maximum response (Max). Bradykinin concentration
responses were biphasic, and were best ﬁtted using a two-
site saturation model, for the characterization of a high
afﬁnity component (PD2-1 and Max-1) and a low afﬁnity
component (PD2-2 and Max-2). Statistical analysis of data
was by Student’s paired or un-paired t-test (two groups of
data, single factor), one-way ANOVA (more than two
groups of data, single factor) or two-way ANOVA (more
than two groups of data, two factors), with Holm–Sidak
post tests where appropriate, and as indicated in ﬁgure or
table legends, using SigmaPlot 10. Differences were consi-
dered signiﬁcant if P < 0.05.
Results
GPCR-mediated contraction of rat bronchioles is dependent on
SrcFK, Rho-kinase and FAK. We examined the contractile
responses to CCh and bradykinin (BK) in rat bronchioles,
whereby the bronchoconstrictors were applied cumulatively
at 5min intervals. Two concentration-response curves were
performed in each bronchiole (0.01–100μM), the ﬁrst acting
as a control and the second after pre-incubation with either
the SrcFK inhibitor PP2 (30 μM), the Rho-kinase inhibitor
Y27632 (10 μM), the FAK inhibitor PF-573228 (10 μM) or no
inhibitor (control). In addition, to account for possible
off-target effects of PP2 and PF-573228, key contractile
responses were also repeated with PP3 (30 μM), the negative
control for PP2 and a dual FAK/PYK2 inhibitor, PF-431396
(10 μM). CCh caused a sustained contraction at each dose
(Figure 1A). The maximum response to CCh was
signiﬁcantly reduced by PP2 (P < 0.01, paired t-test, n = 8),
Y27632 (P < 0.01, paired t-test, n = 6) and PF-573228
(P < 0.05, paired t-test, n = 8), and the PD2 was signiﬁcantly
increased by PP2 (5.55 ± 0.09 vs. control 5.8 ± 0.14,
P < 0.05, paired t-test, n = 8), Y27632 (5.4 ± 0.07 vs. control
5.82 ± 0.07, P < 0.01, paired t-test, n = 6) and PF-573228
(5.21 ± 0.08 vs. control 5.69 ± 0.07, P < 0.001, paired t-test,
n = 8) (Figure 1A–D). PP3 had no signiﬁcant effect on either PD2
(5.6 ± 0.05 vs. control 5.72 ± 0.08, n = 7) or maximum
contraction (144 ± 5% vs. control 149 ± 3%, n = 7).
Conversely, PF-431396 had similar effects as those of
PF-573228, causing a similar increase in PD2 (5.20 ± 0.05
vs. control 5.90 ± 0.07, P < 0.001, paired t-test, n = 7) and
a similar reduction in maximum contraction (139 ± 6.3%
vs. control 176 ± 9.3%, P < 0.001, paired t-test, n = 7)
(Supporting Information Figs. S2A and S3A). In time-
matched control responses, repeated in the absence of
inhibitor, the maximum contraction of the second response
was slightly increased (ﬁrst repeat: 203 ± 22% vs. second
repeat 228 ± 25%, P < 0.01, paired t-test, n=10), but there
was no signiﬁcant change in PD2 (ﬁrst repeat: 5.67 ± 0.11
vs. second repeat 5.63 ± 0.09, n = 10).
Bradykinin caused a prominent transient contraction and
a smaller sustained component at each dose (Figure 1E). The
concentration-dependence of these responses appeared
biphasic. Contraction at all concentrations of BK was
signiﬁcantly inhibited by PP2 (Figure 1F), with maximum
amplitudes of both high and low afﬁnity components being
reduced (Max-1 = 1.66 ± 0.5% vs. control 12.1 ± 4.1%; Max-
2 = 6.81 ± 2.0% vs. control 24.4 ± 6.0%, P < 0.05, n = 11),
while PD2-1 and PD2-2 were both unchanged (PD2-1 = 6.7
± 0.21 vs. control 7.08 ± 0.11; PD2-2 = 4.85 ± 0.27 vs. con-
trol 4.67 ± 0.22, n = 11) (see Supporting Information Fig. S4
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for all BK dose responses curve ﬁt data). BK-induced responses
were nearly abolished by Y27632 (Figure 1G) and abolished
by PF-573228 (Figure 1H), rendering curve ﬁtting impossible.
In time-matched control responses, repeated in the absence
of inhibitor, there were no changes in either Max or PD2
values for either the high or the low afﬁnity component
(not shown).
SrcFKs mediate GPCR-induced Ca2+-sensitization and Rho-kinase
activation, but FAK does not. To clarify whether the effects of
Figure 1
Effects of kinase inhibitors on carbachol and bradykinin-induced contraction in rat bronchioles. Measurement of isometric tension in freshly
isolated rat bronchioles. CCh (A–D) or BK (E–H) was applied cumulatively (0.01–100μM) at 5min intervals. Representative traces show typical
cumulative contractile responses to CCh (A) and BK (E). Arrows indicate the points where the ﬁrst concentration was applied. Two responses were
performed in each bronchiole, the second after application of the Src inhibitor PP2 (30 μM, 10min, B: CCh, n = 8 or F: BK, n = 11), the Rho-kinase
inhibitor Y27632 (10 μM, 10min, C: CCh, n = 6 or G: BK, n = 4), the FAK inhibitor PF-573228 (10 μM, 10min, D: CCh, n = 8 or H: BK, n = 5) or no
inhibitor (not shown). Measurements were taken at the end of each 5min exposure and data ﬁtted by nonlinear regression. Data expressed as a %
of that induced by 80mM KPSS (mean ± SEM); see main text or Supporting Information Fig. S4 for effects on PD2 and max values.
Tyrosine kinases in airway smooth muscle BJP
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kinase inhibitors on bronchoconstrictor-induced contraction
is mediated through a Rho-kinase-dependent Ca2+-
sensitization pathway, CCh or BK concentration-response
curves were repeated in α-toxin-permeabilized rat
bronchioles, with [Ca2+]i ﬁxed at pCa 6.5, in the absence or
presence of PP2, Y27632 or PF-573228. After α-toxin-
permeabilization, bronchoconstictor concentration-
response curves were not repeatable (not shown), so
controls and effects of antagonists were compared in
separate bronchioles. CCh-induced contraction was almost
absent in the presence of Y27632 and was signiﬁcantly
smaller in the presence of PP2 (P < 0.05, unpaired t-test,
n = 9), but in the presence of PF-573228 was not different
from controls (Figure 2B). The PD2 was signiﬁcantly greater
after PP2 (4.64 ± 0.13, vs. control -5.08 ± 0.12, P < 0.05,
unpaired t-test, n = 9), but was no different in PF-573228.
The underlying pCa 6.5 contraction was unaffected by either
PP2 or PF-573228, but was partially inhibited by Y27632 (61 ±
8% block, P < 0.05 vs. absence of Y27632, paired t-test, n = 6).
BK also produced a modest (relative to CCh) concentration-
dependent contraction in permeabilized bronchioles (Figure 2A
and C). The concentration-dependence of these responses again
appeared biphasic, but their small amplitude and poor
sustainability rendered curve-ﬁtting impossible. Nevertheless,
peak responses were signiﬁcantly smaller or absent in the
presence of PP2 or Y27632, respectively, and no different in
PF-573228 (Figure 2C).
To conﬁrm that Rho-kinase is being activated by 30 s
exposure to BK (1 μM) or CCh (100 μM), and whether this
activation relates to subsequent activation of MLCK, we
measured phosphorylation of MYPT-1 at T696, a known
phosphorylation target of Rho-kinase (Feng et al., 1999),
and of MLC20 at S19, the main target of MLCK. Furthermore,
in order to reveal a possible interaction between Rho-kinase
and SrcFK or FAK with relation to MLC20 phosphorylation,
we examined the effects of inhibitors of Rho-kinase, SrcFK
or FAK on both phosphorylation responses in hASMC.
Phosphorylation of MLC20 and MYPT-1 were both signiﬁ-
cantly enhanced by BK. This enhancement was signiﬁcantly
reduced by PP2 and abolished by Y27632 at both sites, while
PF-573228 signiﬁcantly reduced the enhancement of MLC20,
but not MYPT-1 phosphorylation (Figure 2D and F). CCh also
enhanced phosphorylation of both proteins, but to a lesser
extent than BK. Basal MLC20 phosphorylation was insensi-
tive to all three inhibitors (Figure 2E), while basal MYPT-1
phosphorylation was partially sensitive to Y27632, but
insensitive to PP2 or PF-573228 (Figure 2G).
Bronchoconstrictors enhance SrcFK and FAK auto-
phosphorylation. In order to conﬁrm that the inﬂuence of
SrcFK and FAK on contraction and Rho-kinase activity
occurs in direct response to bronchoconstrictor stimulation,
we also examined the effects of BK or CCh on SrcFK auto-
phosphorylation at Y416 and FAK auto-phosphorylation at
Y397, as a reﬂection of respective changes in kinase activity
(Calalb et al., 1995; Xu et al., 1999). In hASMC, auto-
phosphorylation of both kinases was signiﬁcantly enhanced
by both agents (Figure 3 A–D). As expected, SrcFK
phosphorylation was almost abolished by PP2, and FAK
phosphorylation was almost abolished by PF-573228, both
conﬁrming the selectivity of the phospho-antibodies and
validating the choice of kinase inhibitor concentrations used.
In rat trachealis muscle, SrcFK and FAK auto-phosphorylation
were also enhanced by BK and CCh, as was phosphorylation
of MLC20 (S19) and MYPT-1 (Y397), (Figure 3E, F).
Bronchoconstrictor-induced FAK Y397 phosphorylation was
noticeably weaker in rat trachealis than in hASMC.
FAK and SrcFK influence SOCE/ROCE and VOCE. We
examined the effects of PP2 and PF-753228 on VOCE-
mediated contraction by sub-maximal depolarization with
40mM KPSS. In control experiments, contraction amplitude
induced by two consecutive KPSS exposures was not
signiﬁcantly different, while when PP2 (30 μM) or PF-
573228 (10 μM) was applied between the ﬁrst and second
exposures, the contractile response was modestly but
signiﬁcantly reduced by PF-573228, but not by PP2
(Figure 4A and B). To rule out a direct Ca2+-channel
antagonist effect of PF-573228, we also examined its effect
on contraction induced by maximal depolarization with
80mM KPSS. This contraction was signiﬁcantly less
sensitive to PF-573228 than the 40mM KPSS contraction
(11.5 ± 2.7% inhibition, n = 6, vs. 30.2 ± 6.3% inhibition of
40mM KPSS, n = 7; P < 0.05 by unpaired t-test). We then
examined the effects of PP2 and PF-573228 on SOCE-
mediated contraction. SR Ca2+ was ﬁrst depleted with
cyclopiazonic acid (CPA, 10 μM) in the absence of
extracellular Ca2+ and presence of 200 μM EGTA, then 2mM
Ca2+ was re-applied. CPA was used here instead of a GPCR
agonist because it would have been difﬁcult to separate
effects of the agonist on Ca2+ entry from those on Rho-
kinase-mediated Ca2+ sensitization. In control experiments,
re-application of 2mM Ca2+ induced a biphasic contraction,
which peaked at ~2min and slowly decayed to ~20% of
80mM KPSS after 30min. In the presence of either PP2 or
PF-573228, the sustained component was signiﬁcantly
smaller, decaying to <10% of 80mM KPSS after 30min
(Figure 4C and D). PP3 was without signiﬁcant effect on this
response, ruling out the possibility of a non-speciﬁc SOCE
blocking effect of PP2 (Supporting Information Fig. S2B),
while PF-431396 inhibited the response in a near-identical
way to that of PF-573228, supporting a speciﬁc role for FAK
in this response (Supporting Information Fig. S3B). To see
whether these effects of PP2 and PF-573228 were due to an
effect of SrcFK or FAK on SOCE itself or on secondary
activation of VOCE, the effect of the SOCE blocker
YM58483 (10 μM) and the Ca2+ channel antagonist
nifedipine (2 μM) on the SOCE-mediated contraction was
also determined. Apart from a small residual transient
contraction, the response was abolished by YM58483, while
nifedipine was without effect, apart from a small reduction
in the peak response (Figure 4D).
To support contraction data and to further eliminate
the possibility that SrcFK and FAK were indirectly
inﬂuencing SOCE via an action on SR Ca2+ release, we
also examine the effects of PP2 and PF-753228 on SOCE
[Ca2+]i responses in Fura-2 loaded hASMC, using BK as
the initial SR-emptying stimulus. After the recording of
an initial baseline in 2mM Ca2+, and then for 5min in
nominally Ca2+-free buffer, the addition of BK (1 μM)
caused a near instantaneous increase in [Ca2+]i. This
decayed back to the baseline within ~2min; a response
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Figure 2
Effects of kinase inhibitors on contraction in α-toxin permeabilized rat bronchioles andMLC20/MYPT-1 phosphorylation in hASMC. (A–C)Measurement
of isometric tension in α-toxin permeabilized rat bronchioles. All responses were performed with pCa ﬁxed at 6.5 and in the presence of 10μMCPA and
1 μMGTP. (A) Representative traces showing CCh (upper panel) or BK (lower panel) being applied cumulatively (0.01–100 μM) at 5min intervals, with
arrows indicating where the ﬁrst dosewas applied. Responses were performed in the absence of inhibitor (control) or after pre-incubation with either the
Src inhibitor PP2 (30 μM, 10min), the Rho-kinase inhibitor Y27632 (10 μM, 10min) or the FAK inhibitor PF-573228 (10 μM, 10min). Measurements
were taken at the end of each 5min exposure. Data are expressed as a%of that induced by pCa 4.5 (mean ± SEM). (B) CCh datawere ﬁtted by nonlinear
regression (control, n = 10; PP2, n = 9; Y27632, n = 4; PF-573228, n = 11); see main text for effects on CCh PD2. (C) BK data could not be ﬁtted by
nonlinear regression so were compared by two-way RM ANOVA (control, n = 6; PP2, n = 6; Y27632, n = 4; PF-573228, n = 6; *P < 0.05, **P < 0.01
vs. control). (D–G)Measurement of phosphorylation of MLC20 at S19 (P-MLC20, D, E) andMYPT-1 at T696 (P-MYPT-1, F, G), in hASMC. Representative
blots show effects of treatment on ‘phospho’ and ‘total’ immunoreactivity for each protein. Bar charts show the effects of treatments on the degree of
phosphorylation (mean ± SEM), expressed as a%of values fromuntreated (control) samples run on the samegels. (D) Effects of BK (1μM30 s) onMLC20
phosphorylation in the absence of inhibitor (n = 16) or after pretreatment with either PP2 (30 μM, 10min, n = 11), Y27632 (10 μM, 10min, n = 9)
or PF-573228 (PF, 10 μM, 10min, n = 11). (E) Effects of inhibitors on basal MLC20 phosphorylation (n = 4–11). (F) Effects of BK (1 μM, 30 s) on
MYPT-1 phosphorylation in the absence of inhibitor (n = 13), or after pre-application of PP2 (30 μM, 10min, n = 13), Y27632 (10 μM, 10min,
n = 13), or PF-573228 (10 μM, 10min, n = 8). (G) Effects of inhibitors on basal MYPT-1 phosphorylation (n = 4–11). Comparisons were by one-
way ANOVA with Holm–Sidak post tests: *P < 0.05 and **P < 0.01 versus control; #P < 0.5 and ##P <0.01 versus BK alone.
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typical of GPCR-induced SR Ca2+-release. 2mM Ca2+ was
then re-applied for 20min, with simultaneous washout
of BK. This induced a biphasic rise in [Ca2+]i with a similar
time course to the SOCE contractile responses. In the
presence of either PP2 or PF-573228, the sustained com-
ponent was reduced by ~50%, while the initial transient
component and the initial BK-induced SR release were both
unaffected (Figure 5).
Interaction between SrcFK and FAK. Because SrcFK and FAK
appear to be sharing some but not all of the contraction
signalling pathways investigated in this study, and in the
Figure 3
Effects of broncoconstrictors on SrcFK and FAK auto-phosphorylation in hASMC and rat trachealis. (A–D) Measurements of auto-phosphorylation
of SrcFK at Y416 (P-SrcFK, A, B) and auto-phosphorylation of FAK at Y397 (P-FAK, C, D) in hASMC. Representative blots show effects of treatments
on ‘phospho’ and ‘total’ immunoreactivity for each protein. Bar charts show the effects of treatments on the degree of phosphorylation (mean ±
SEM), expressed as a % of values from untreated (control) samples run on the same gels. (A) Effect of BK (1 μM, 30 s) in the absence (n = 12) or
presence of PP2 (30 μM, 10min, n = 7) on P-SrcFK (Y416). (B) Effect of CCh (100 μM, 30 s) in the absence (n = 13) or presence of PP2 (n = 8) on
P-SrcFK (Y416). (C) Effect of BK in the absence (n = 15) or presence of PF-573228 (PF, 10 μM, 10min, n = 13) on P-FAK (Y397). (D) Effect of CCh in
the absence (n = 16) or presence of PF-573228 (n = 11) on P-FAK (Y397). Comparisons by one-way ANOVA with Holm–Sidak post tests: **P< 0.01
versus control; ##P< 0.01 versus BK or CCh alone. (E, F) Measurements of phosphorylation of MLC20 (S19), MYPT-1 (T696), SrcFK (Y416) and FAK
(Y397) in rat trachealis muscle. (E) Effects of BK (1 μM, 30 s, n = 8). (F) Effects of CCh (100 μM, 30 s, n = 8). Comparisons by unpaired t-test:
*P<0.05, **P<0.01 versus control.
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light of previous evidence suggesting cooperation between
the two kinases, we investigated the inﬂuence of FAK on
SrcFK auto-phosphorylation and vice versa. Enhancement of
SrcFK (Y416) auto-phosphorylation by BK was inhibited by
PF-573228 by ~50% (Figure 6A), while basally, this
phosphorylation was insensitive to PF-573228 but inhibited
by PP2 (Figure 6B). FAK kinase activity is also reportedly
inﬂuenced by Src-dependent phosphorylation on FAK
Y576/577 (Calalb et al., 1995). Phosphorylation at this dual
site was enhanced by BK, and this enhancement was nearly
abolished by PP2 and partially inhibited by PF-573228
(Figure 6C), while basally, this phosphorylation was inhibited
by PP2, but not PF-573228 (Figure 6D). However, BK-induced
enhancement of FAK (Y397) auto-phosphorylation was
Figure 4
Effects of SrcFK and FAK inhibitors on VOCE- or SOCE-associated contraction in rat bronchioles. (A, B) VOCE-associated contractions induced by
40mM KPSS. Representative traces (A) andmeanmeasurements of peak amplitude (B, ± SEM), showing effects of two contractions in the absence
of inhibitor (left panels, n = 8), the effect of PF-573228 on the second contraction (PF, middle panels, 10 μM, 5min pre-incubation, n = 7) or the
effect of PP2 on the second contraction (30 μM, right panels, 5min pre-incubation, n = 9). Comparisons by paired t-test: **P< 0.01 versus control.
(C, D) SOCE-associated contraction induced by 10 μM CPA/200 μM EGTA/zero Ca2+, followed by re-application of 2mM Ca2+. Representative
traces (C) and mean measurements of amplitude of contractile responses at 2min intervals after re-application of Ca2+ (D, ± SEM), showing
control response (n = 14) and effects of pre-incubation with PF-573228 (n = 9), PP2 (n = 9), nifedipine (n = 10) or YM58483 (n = 5). Comparisons
by two-way ANOVA with Holm–Sidak post tests: *P < 0.05 for control versus PF-573228 or PP2. #P<0.01 for control versus YM58483. ^P < 0.05
for control versus nifedipine at 2min only.
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unaffected by PP2 (Figure 6E). Basal phosphorylation of FAK
(Y397) was also insensitive to PP2, but was inhibited by
PF-53228 (Figure 6F).
c-Src is the principle SrcFK mediating bronchoconstrictor-induced
phosphorylation responses. Multiple members of the Src-
family of kinases are expressed in ASM, including c-Src, Fyn,
Yes and Lyn (Sakai et al., 2010). For this reason, and the fact
that the phospho-SrcFK antibody cannot distinguish
between Src family members, we re-examined the effects of
acute BK treatment on MLC20 (S19), MYPT-1 (T696), SrcFK
(Y416) and FAK (Y576/577) phosphorylation in hASMC after
transfection with c-Src siRNA or scrambled siRNA. Speciﬁcity
of c-Src siRNA was veriﬁed by a ~70% reduction in c-Src
Figure 5
Effects of SrcFK and FAK inhibitors on SOCE/ROCE-associated [Ca2+]i responses in hASMC. A: Representative control trace of [Ca
2+]i in Fura-2
loaded hASMC, as determined by the ratio of ﬂuorescence at 340 nm/380 nm. Arrow indicates the point at which pre-stimulus basal [Ca2+]i
was recorded in 2mM [Ca2+]o (and extrapolated by dashed line). The buffer was then switched to zero [Ca
2+]o until a new baseline was
established, and 1 μM BK added for 5min. Finally, 2mM [Ca2+]o was reapplied for 20min. Responses were performed either in the absence or
presence of FAK inhibitor PF-573228 (B, C: PF, 10 μM, added 5min prior to BK, n = 15 vs. 15 matched controls) or SrcFK inhibitor PP2 (D, E:
30 μM, added 5min prior to BK, n = 10 vs. eight matched controls). Measurements were made of the peak BK-induced transient (B, D:
arbitrary units, mean ± SEM) and of the response to reapplication of 2mM [Ca2+]o (C, E: arbitrary units, measured at 1min intervals, mean ± SEM),
compared with the pre-stimulus basal [Ca2+]i in 2mM [Ca
2+]o (indicated by arrows). Background ﬂuorescence (in zero [Ca
2+]o, prior to the applica-
tion of BK) was subtracted from all other measurements. Comparisons by un-paired t-test (B, D) or two-way ANOVAwith Holm–Sidak post tests (C, E:
*P < 0.05 vs. matched controls).
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protein expression, while expressions of MLC20, MYPT-1 and
FAK were all unaffected (Figure 7A). The scrambled siRNA had
no effect on any of the proteins examined. c-Src siRNA
inhibited BK-induced phosphorylation of MLC20 by ~80%,
while responses of MYPT-1 (T696), SrcFK (Y416) and FAK
(Y576/577) to BK were all inhibited by ~60%, compared with
matched scrambled siRNA transfected cells (Figure 7 B–D).
Discussion
We examined the role of SrcFK and FAK kinase activity in
bronchoconstrictor-induced contraction of rat-isolated
bronchioles and in [Ca2+]i and phosphorylation responses
in hASMC. Contraction was induced and MLC20 phosphor-
ylation was enhanced by the bronchoconstrictors BK and
Figure 6
Interaction between SrcFK and FAK in response to BK in hASMCs. Measurements of auto-phosphorylation of SrcFK at Y416 (P-SrcFK, A, B),
phosphorylation of FAK at the Y576/577 dual site (C, D), and auto-phosphorylation of FAK at Y397 (P-FAK, E, F) in hASMC. Representative blots
show effects of treatments on ‘phospho’ and ‘total’ immunoreactivity for each protein. Bar charts show the effects of treatments on the degree of
phosphorylation (mean ± SEM), expressed as a % of values from untreated (control) samples run on the same gels. (A) Effects of BK (1μM, 30 s) on
P-SrcFK (Y416) in the absence (n = 14) or presence of the FAK inhibitor PF-573228 (PF, 10μM 10 min, n = 7). (B) Effects of PF (n = 4) or the SrcFK
inhibitor PP2 (30μM, 10 min, n = 4) on basal P-SrcFK (Y416). (C) Effects of BK on P-FAK (Y576/577) in the absence (n = 11) or presence of PP2
(n = 6) or PF (n = 7). (D) Effects of PF (n = 4) or PP2 (n = 5) on basal P-FAK (Y576/577). (E) Effect of BK on P-FAK (Y397) in the absence (n = 14)
or presence of PP2 (n = 4). (F) Effects of PF (n = 4) or PP2 (n = 4) on basal P-FAK (Y397). Comparisons by one-way ANOVA with Holm–Sidak post
tests: **P < 0.01 versus control or ##P < 0.01 versus BK alone.
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CCh, and these responses were sensitive to inhibition of
both SrcFK and FAK. Using auto-phosphorylation as an in-
dication of kinase activity, both SrcFK and FAK were acti-
vated by both agents in hASMC and rat trachealis,
suggesting an important role for these kinases in GPCR-
induced ASM contraction in both humans and rodents.
PP3, the negative control for PP2, was without effect on
contraction, while PF-431396, another inhibitor of FAK,
had similar effects as PF-573228, reducing the likelihood
of our results being inﬂuenced by non-speciﬁc effects of PP2
or PF-573228. Amongst the several Src family members, both
c-Src and Fyn have been implicated in vascular smooth mus-
cle contraction (Nakao et al., 2002; Knock et al., 2008), and
Lyn is activated by muscarinic agonists in ASM (Pertel et al.,
2006). Here however, the effects of c-Src siRNA suggest that
60–80% of all the bronchoconstrictor-induced phosphoryla-
tion responses investigated herein were speciﬁcally mediated
by c-Src.
Figure 7
Effects of c-Src siRNA on bronchoconstrictor-induced MLC20, MYPT-1, SrcFK and FAK phosphorylation in hASMCs. Measurement of protein
expression and phosphorylation responses to BK (1 μM, 30 s) in hASMCs after transfection with c-Src siRNA or scrambled siRNA (scram). (A) Effect
of c-Src siRNA on c-Src protein expression and (lack of) effect onMLC20, MYPT-1 and FAK expression. Data normalized to GAPDH expression in the
same samples (arbitrary units, n = 8–12). Comparisons by unpaired t-test: **P < 0.01 versus scram siRNA. (B) Effect of BK on MLC20 phosphory-
lation at S19 (P-MLC20) after transfection with scram siRNA (n =16) or c-Src siRNA (n = 16). (C) Effect of BK on MYPT-1 phosphorylation at T696
(P-MYPT-1) after transfection with scram siRNA (n = 14) or c-Src siRNA (n = 14). (D) Effect of BK on SrcFK phosphorylation at Y416 (P-SrcFK) after
transfection with scram siRNA (n = 16) or c-Src siRNA (n = 16). (E) Effect of BK on FAK phosphorylation at Y576/577 (P-FAK) after transfection with
scram siRNA (n = 10) or c-Src siRNA (n = 10). Comparisons by two-way ANOVA: **P < 0.01 versus control; ##P < 0.01 versus scram siRNA.
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To further characterize the signalling pathways through
which SrcFK and FAK mediate ASM contraction, we ﬁrst fo-
cussed on their role in Rho-kinase dependent Ca2+-sensitiza-
tion, a process whereby inhibition of MLCP results in
enhanced MLC20 phosphorylation, and hence force genera-
tion, without the requirement for an increase in [Ca2+]i
(Somlyo and Somlyo, 2003). Both BK and CCh-induced con-
traction were highly sensitive to Rho-kinase inhibition with
Y27632. Furthermore, a component of the contractile re-
sponse to both BK and CCh persisted when bronchioles were
permeabilized with α-toxin to prevent changes in intracellu-
lar Ca2+. We found that these contractile responses were
dependent on Rho-kinase and SrcFK, but not FAK. Further-
more, we found that MYPT-1 phosphorylation on T696, an
indicator of Rho-kinase-mediated MLCP inhibition (Feng
et al., 1999), is also enhanced by BK and CCh and that this
enhancement is sensitive to inhibition of Rho-kinase and
SrcFK, but not of FAK. This inﬂuence of SrcFK on Rho-kinase
activity occurred speciﬁcally in response to agonist stimula-
tion, because baseline phosphorylation of MYPT-1 and
MLC20 and baseline pCa6.5 contraction in permeabilized
bronchioles were not affected by SrcFK inhibition. Clearly,
these results indicate that SrcFK mediates GPCR-induced
smooth muscle contraction in part via activation of Rho-
kinase. Importantly, this is the ﬁrst direct demonstration of
an interaction between SrcFK and Rho-kinase in ASM and in
vessels of a size relevant to the control of airway resistance,
consistent with the implied importance of Rho-kinase in
airway hyper-responsiveness from studies in whole animal
or isolated upper airways (Yoshii et al., 1999; Schaafsma
et al., 2006). Interestingly, receptor TK stimulation also
induces Rho-kinase-dependent ASM contraction (Gosens
et al., 2004), and other responses of ASM to growth factor
stimulation are also SrcFK-dependent (Krymskaya et al., 2005).
Thus SrcFK may be a point of convergence for the activation of
Rho-kinase in response to either GPCR or growth factors.
Rho-kinase is directly activated by the small G-protein
RhoA, which is itself activated by guanine nucleotide
exchange factors (RhoGEFs). RhoGEFs are known to be acti-
vated or modulated by various non-receptor TKs (Chikumi
et al., 2002; Ying et al., 2009; Guilluy et al., 2010), in addition
to G12/13 binding. It is therefore conceivable that SrcFK may
be activating RhoA/Rho-kinase via direct phosphorylation
of a RhoGEF. Alternatively, they may do so via the prior acti-
vation of another kinase, such as FAK, PYK2 or JAK2 (Calalb
et al., 1995; Andreev et al., 2001; Singh et al., 2011). Our
results are not inconsistent with this hypothesis, but exclude
FAK as the intermediary kinase in this instance.
We next focussed on the role of SrcFK and FAK in Ca2+ sig-
nalling. Gq/PLC-β-coupled GPCRs induce Ca2+ entry through
three main pathways: DAG-sensitive TRP channel opening
(ROCE), IP3-dependent depletion of SR Ca
2+ and subsequent
STIM1/Orai1/TRP-dependent inﬂux (SOCE), and subsequent
depolarization-induced opening of L-type Ca2+ channels
(VOCE) (Kawasaki et al., 2006; Wang et al., 2008). Several
members of the TRPC family of channels, in addition to being
modulated by DAG, are subject to modulation by phosphory-
lation, and tyrosine phosphorylation of TRPC channels is
SrcFK-dependent, contributing to either ROCE or SOCE
(Kawasaki et al., 2006). Moreover, association of STIM1 with
Orai1 in response to SR depletion, and subsequent Ca2+
inﬂux, is partially dependent on SrcFK-mediated phosphory-
lation of STIM1 (Lopez et al., 2012). In accord with these pre-
vious studies, we found that CPA-induced SOCE-dependent
contraction in rat bronchioles and BK-induced Ca2+ inﬂux
in hASMC were both similarly sensitive to SrcFK inhibition.
Interestingly, we found that these responses were also
similarly sensitive to FAK inhibition. This, to our knowledge,
is the ﬁrst indication that FAK may be contributing to GPCR-
induced Ca2+ responses and contraction in human and
rodent ASM, via upstreammodulation of SOCE and/or ROCE.
Some GPCR agonists, notably angiotensin II, also mediate SR
Ca2+ release via SrcFK-dependent tyrosine phosphorylation
of PLC-γ (Schmitz et al., 1997). However, there is no indi-
cation that this is occurring in our study, because we found
that neither PP2 nor PF-573228 altered the BK-induced Ca2+
transients indicative of SR release.
Our ﬁnding that the CPA-induced SOCE contraction
was minimally affected by the Ca2+ channel antagonist
nifedipine suggests that VOCE secondary to SOCE-induced
depolarization was not contributing substantially to this
response. However, VOCE may also be activated more
directly via a number of signalling pathways including
stretch-activated phosphatidylcholine-speciﬁc PLC-derived
DAG (Mauban et al., 2015) or integrin-directed tyrosine
phosphorylation. Regarding the latter, engagement of
integrin α5β1 induces SrcFK and FAK-dependent phosphory-
lation of the α1c subunit of the L-type Ca2+ channel in
vascular smooth muscle, with the likeliest sequence of
events being integrin-induced FAK auto-phosphorylation
followed by SrcFK recruitment by FAK (Owen et al., 1999;
Salazar and Rozengurt, 2001) and subsequent direct phos-
phorylation of the channel by SrcFK (Wu et al., 2001; Gui
et al., 2006). Similarly in ASM, VOCE may also be enhanced
via stretch or adhesion-induced FAK activity (Smith et al.,
1998; Tang et al., 1999). In bronchioles, we found that
contraction induced by depolarization with sub-maximal
(40mM) K+ was sensitive to PF-573228 but not PP2, which
suggests that FAK may be activating VOCE independently
of SrcFK. However, contraction induced by maximum depo-
larization with 80mMK+ was considerably less sensitive to
PF-573228, ruling out a non-speciﬁc effect of PF-573228 on
Ca2+ channel opening per se. We did not systematically
examine the effects of stretch on contractile responses, as
carried out previously in trachea (Tang et al., 1999), but
applied a standard degree of stretch to maximize active
tension responses to bronchoconstrictors or KPSS. Similarly,
adherent hASMC are assumed to be under a degree of
self-induced basal tension (Deguchi et al., 2005). In light of
this, it is worth noting that the relatively weak FAK auto-
phosphorylation observed in trachealis samples treated with
BK or CCh, compared with similarly treated hASMC, may
have been because no stretch was applied to trachealis
samples during BK or CCh treatment prior to snap freezing
for protein extraction.
In smooth muscle contraction, it has been assumed that
the mutual dependence between SrcFK and FAK relates pri-
marily to the recruitment of contractile ﬁbres through actin
polymerization and focal attachment formation (Gerthoffer
and Gunst, 2001; Tang et al., 1999; Gunst et al., 2003). It is
therefore of note that we only see possible evidence of such
mutuality with regard to SOCE/ROCE activity, but not in
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relation to Rho-kinase activation (SrcFK only) or VOCE
activity (FAK only). The selective sensitivity of basal SrcFK
auto-phosphorylation to PP2 and of basal FAK auto-
phosphorylation to PF-537228 conﬁrms the speciﬁcity of
these two antagonists for their intended targets at the
concentrations used in this study. Therefore, our ﬁnding that
BK-induced SrcFK auto-phosphorylation is partially PF-
537228-sensitive suggests a partial dependence of GPCR-
induced SrcFK activity on FAK. This is probably because SrcFK
can be activated via disruption of intramolecular auto-
inhibition by association of the SH2 domain with the phos-
phorylated Y397 of FAK (Xing et al., 1994). Conversely, we
show that BK-induced FAK auto-phosphorylation is wholly
independent of SrcFK activity. In response to adhesion, in
non-muscle cells, FAK auto-phosphorylation is enhanced by
SrcFK-mediated phosphorylation on Y576/577 (Calalb et al.,
1995; Salazar and Rozengurt, 2001). However, despite the fact
that we show that FAK Y576/577 phosphorylation is also
induced by BK and almost entirely SrcFK-mediated, this
phosphorylation does not correlate with enhanced FAK auto-
phosphorylation. A similar discrepancy was observed in
ﬁbroblasts where adhesion-induced FAK auto-phosphorylation
was SrcFK-dependent but GPCR-induced FAK auto-
phosphorylation was not, despite both stimuli inducing
SrcFK-dependent Y576/577 phosphorylation (Salazar and
Rozengurt, 2001). Taken together, our results imply two
things about these interactions in ASM: ﬁrstly, that GPCR
can induce FAK activation without prior activation of SrcFK,
and secondly, that there may be two sub-populations of
BK/CCh-activated SrcFK; one FAK-dependent, resulting in
modulation of SOCE/ROCE, and the other FAK-independent,
resulting in activation of Rho-kinase (as summarized in
Figure 8).
In conclusion, our data suggest an important role for
SrcFK and FAK in bronchoconstrictor-mediated contraction
in ASM, with the two kinases acting together to induce
SOCE/ROCE, and independently to mediate Rho-kinase-
dependent Ca2+ sensitization and VOCE respectively. These
ﬁndings may inform the search for new drug targets for the
treatment of obstructive lung diseases such as asthma, and
in particular, support the suggested key role for SrcFK in
experimental airway hyper-responsiveness (Sakai et al.,
2010; Katsumoto et al., 2013).
Acknowledgements
Thanks to Mrs Kheem Jones and other NHS staff for patient
recruitment and provision of bronchoscopy biopsies. This
work was supported by the National Institute for Health
Research (NIHR) Biomedical Research Centre based at Guy’s
and St Thomas’ NHS Foundation Trust and King’s College
London. The views expressed are those of the author(s) and
not necessarily those of the NHS, NIHR or the Department
of Health.
Figure 8
Proposed role for SrcFK and FAK in bronchoconstrictor or depolarization-induced ASM contraction, based on the results of the current study and
existing literature. (A) GPCR activate both SrcFK and FAK, presumably via interaction with heterotrimeric G-protein sub-units (e.g. Gαq, Gα12/13
or Gβγ) or downstream signalling molecules. Activated SrcFK forms two distinct sub-populations: one FAK-independent and one FAK-dependent.
(B) FAK-independent SrcFK induces Rho-kinase to phosphorylate MYPT-1, thus enhancing myosin light-chain phosphorylation (P-MLC) through
inhibition of myosin light-chain phosphatase (MLCP). SrcFK are perhaps activating Rho-kinase via the tyrosine phosphorylation of RhoA-
associated proteins such as RhoGEFs. (C) A FAK/Src complex may be mediating store-operated and/or receptor-operated Ca2+ entry (SOCE/
ROCE) via the tyrosine phosphorylation of TRP channels, or associated signalling proteins, such as STIM1, in association with DAG. (D) FAK is also
independently enhancing voltage-operated Ca2+ entry (VOCE), perhaps via direct phosphorylation of voltage-dependent Ca2+ channels, in
response to the additional stimulus of stretch or cellular adhesion, via integrin engagement.
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